IGF-1 DES (Des(1-3) IGF-1)

Truncated IGF-1 Analog · Localized Muscle Growth

Overview

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.

IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.

Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.

Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.

Accelerates local tissue recovery in the injected muscle group after training.

Promotes repair and regeneration at the injection site through IGF-1R activation.

Mechanism

Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.

Research areas

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.
Site-specific muscle growth via direct intramuscular injection into target muscle post-workout.
Stimulates satellite cell proliferation and differentiation, potentially creating new muscle fibers.
Accelerates local tissue recovery in the injected muscle group after training.
Promotes repair and regeneration at the injection site through IGF-1R activation.

Research notes

Hypoglycemia -- consume carbohydrates after injection
Localized swelling and soreness at injection site
Increased pump in targeted muscles
Mild lightheadedness shortly after injection
Severe or recurring hypoglycemia despite carbohydrate intake
Disproportionate or asymmetric muscle growth
Unusual growths, lumps, or rapid mole changes
Persistent pain, redness, or infection at injection site
Signs of systemic IGF-1 excess (jaw growth, organ enlargement)
Not approved for human use -- research chemical only
Cancer history or active malignancy (IGF-1 promotes cell proliferation)
Diabetes or impaired glucose regulation
WADA prohibited substance -- causes failed drug tests

Reported effects in literature

IGF-1 promotes cell proliferation, and elevated systemic IGF-1 is linked to multiple cancers in the UK Biobank study. DES minimizes systemic exposure through its short half-life and local injection, but cancer risk remains a theoretical concern with any IGF-1 product.

Pharmacokinetics

IGF-1 DES (Des(1-3) IGF-1) is a truncated analog of insulin-like growth factor-1, missing the first three N-terminal amino acids. This structural modification eliminates binding to IGF binding proteins (IGFBPs), meaning 100% of the peptide is bioactive rather than being sequestered in circulation. The result is approximately 10x greater potency than native IGF-1, but with an extremely short half-life of 20-30 minutes. This short duration of action is considered a feature rather than a limitation -- it allows for site-specific injection into target muscles immediately post-workout, promoting localized growth with reduced systemic exposure.
IGF-1 DES activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt/mTOR and MAPK/ERK signaling pathways, driving both muscle hypertrophy and hyperplasia. Because it lacks the tripeptide Gly-Pro-Glu at the N-terminus, it cannot bind to IGFBPs that normally sequester ~98% of circulating IGF-1. This means the entire administered dose remains bioavailable. The very short half-life confines its activity to the local injection site, where it stimulates satellite cell proliferation and differentiation, protein synthesis, and nutrient uptake in the targeted muscle tissue.

References

FAQs

Why is IGF-1 DES injected directly into muscles?

IGF-1 DES has a 20-30 minute half-life and doesn't bind IGF binding proteins, making it 10x more potent but short-acting. Direct intramuscular injection confines its activity to the targeted muscle immediately post-workout, enabling localized hypertrophy without systemic IGF-1 excess.

Will IGF-1 DES cause hypoglycemia?

Yes. IGF-1 DES lowers blood glucose by promoting glucose uptake into muscle tissue. You must consume 20-40g of fast carbohydrates immediately after injection. Monitor blood glucose early in use and never inject before sleep due to overnight hypoglycemia risk.

Can I use IGF-1 DES if I'm on a keto diet?

Not safely. The mandatory carbohydrate intake after IGF-1 DES injection will break ketosis. If keto is your goal, use alternatives like GH or ipamorelin instead. The post-injection carbs are non-negotiable for safety.